Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Summit Therapeutics (SMMT) Stock Price & Analysis

SMMT Stock Chart & Stats

$16.03-$0.17(-1.05%)
At close: 4:00 PM EDT
$12.5$15$17.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$15.57 - $16.43
52-Week Range
$12.07 - $29.23
Previous Close
$16.20
Volume
4.23M
Average Volume (3M)
6.17M
Market Cap
$12.82B
Enterprise Value
$10.67B
Total Cash (Recent Filing)
$690.68M
Total Debt (Recent Filing)
$20.38M
Price to Earnings (P/E)
―
Beta
2.01
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.28
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase III Clinical Efficacy

Consistent efficacy across multiple Phase III studies supports ivonescimab’s potential differentiation in oncology rather than reliance on a single trial. Repeated survival signals can strengthen regulatory, partnering, and commercial prospects across several cancer indications over the next several quarters.

Strategic AstraZeneca Partnership

A large strategic investment from AstraZeneca provides external validation of ivonescimab and strengthens Summit’s capitalization for late-stage development. The accompanying combination work also expands access to a major oncology partner and may improve the asset’s competitive positioning.

Broadening Oncology Pipeline

A broad, multi-indication development program gives Summit several potential paths to create long-term value from ivonescimab. Multiple trials and external collaborations diversify clinical opportunities, increase patient and investigator exposure, and support platform-like strategic relevance.

Bears Say

Pre-revenue And Large Losses

Without a meaningful revenue base, Summit’s financial outlook depends heavily on clinical and regulatory success rather than established commercial cash flows. Continued large losses limit earnings visibility and mean that any delay in development or approval could extend the period before profitability.

High And Rising Cash Burn

Heavy operating cash consumption reduces the time available to fund Summit’s extensive clinical program from existing resources. Rising trial and research spending can accelerate financing needs, increase execution pressure, and make sustained progress dependent on continued access to external capital.

Regulatory And Statistical Uncertainty

The pending FDA decision remains a material business risk because approval depends on an overall-survival standard that has not yet received agency feedback. Multiple interim analyses, differing regional maturity, and possible requests or delays could complicate interpretation and timing.

Summit Therapeutics News

SMMT FAQ

What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $12.07 and its highest was $29.23 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $12.82B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 9 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.006.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 799,726,440 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went down -8.812%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Hedge funds hold Summit Therapeutics shares: the largest hedge-fund position in Summit Therapeutics is 70,144,171 shares, and hedge funds decreased their holdings by 3.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology